UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported):  December 5, 2007

Senesco Technologies, Inc.

(Exact Name of Registrant as Specified in Charter)

 

Delaware

 

001-31326

 

84-1368850

(State or Other Jurisdiction
of Incorporation)

 

(Commission File Number)

 

(IRS Employer Identification No.)

 

303 George Street, Suite 420, New Brunswick, New Jersey

 

08901

(Address of Principal Executive Offices)

 

(Zip Code)

 

(732) 296-8400

(Registrant’s telephone number,

including area code)

 

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

o    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

 

 


 

Item 8.01 Other Events.

                On December 5, 2007, Senesco Technologies, Inc. (the “Company”) announced that it has initiated preclinical lab studies at Mayo Clinic focused on multiple myeloma.  These studies will further test the ability of Senesco’s Factor 5A gene technology to up-regulate apoptosis of cancer cells.  Additionally, the studies will evaluate delivery molecules for encapsulation of Factor 5A to enhance the time the gene will circulate in the bloodstream before clearance by the body.

 

The data gathered from these animal experiments, together with the results of other Factor 5A studies, will be reviewed to determine its sufficiency for submission of a protocol to Mayo Clinic for human studies and to the Food and Drug Administration for an Investigational New Drug Application.

 

                On December 5, 2007, the Company issued a press release announcing the initiation of preclinical studies. A copy of this press release is furnished as Exhibit 99.1.

 

Item 9.01.      Financial Statements and Exhibits.

(d)   Exhibits.

 

 

Exhibit No.

 

Description

 

 

 

 

 

99.1

 

Press Release of Senesco Technologies, Inc. dated December 5, 2007.

 

2


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

SENESCO TECHNOLOGIES, INC.

 

 

 

 

Dated: December 5, 2007

By:

/s/ Bruce Galton

 

 

Name:

Bruce Galton

 

Title:

President and Chief Executive Officer

 

 

3